← Back to Clinical Trials
RecruitingNCT06309719

Hyaluronic Acid and Polynucleotides for Supra-bony Defects

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionPeriodontal Diseases
SponsorQueen Mary University of London
Study TypeINTERVENTIONAL
PhaseN/A
Enrollment24
SexALL
Min Age18 Years
Max AgeN/A
Start Date2024-10-21
Completion2026-12
Interventions
Periodontal Access Flap (AF) + Combined Formulation of Hyaluronic acid and Polydeoxyribonucleotides (PNHA)Periodontal Access Flap (AF)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this pilot study is to describe the early wound healing molecular events and the vascularization pattern associated with the treatment of supra-bony defects with access flap alone or in association with a combined formulation of hyaluronic acid and polydeoxyribonucleotides gel.

Eligibility Criteria

Inclusion Criteria: * Systemically healthy males and females ≥18 years old * Stage III or IV periodontitis (Papapanou, Sanz et al. 2018) * Presence of supra-bony periodontal defects (i.e., defects where the base of the pocket is located coronal to the alveolar crest and characterized by a predominantly horizontal pattern of tissue destruction) confirmed clinically and radiographically at a minimum of two and a maximum of four adjacent teeth and with a probing pocket depth (PPD) \> 5 mm, following non-surgical periodontal therapy (NSPT). If \>4 adjacent teeth exhibited the above clinical and radiographic conditions, the four adjacent teeth showing the greatest overall loss of periodontal attachment were included. Wisdom teeth and second molars will not be considered for the study. If defect presents with an intrabony component, this should be ≤2 mm. * Non-surgical periodontal treatment (step 1 and 2) completed within the previous 4 months * Full-mouth bleeding score (FMBS) and full-mout

Related Trials